Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F] Fluoro-A-85380 PET Special Issue on Cognitive Enhancers

• Published in: Psychopharmacologia Vol. 202; no. 1-3; pp. 79 - 91
• Main Authors: ELLIS, J. R, NATHAN, P. J, SAVAGE, G, ROWE, C. C, VILLEMAGNE, V. L, MULLIGAN, R. S, SAUNDER, T, YOUNG, K, SMITH, C. L, WELCH, J, WOODWARD, M, WESNES, K. A
• Format: Journal Article
• Language: English
• Published: Berlin Springer 2009
• Subjects: Adult and adolescent clinical studies; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Medical sciences; Neurology; Neuropharmacology; Organic mental disorders. Neuropsychology; Pharmacology. Drug treatments; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Agonist; Galantamine; Galantamine . Nicotinic receptors; Alzheimer disease; Benzazepine derivatives; Esterases; Cognition; Acetylcholinesterase; Alkaloid; Cholinergic receptor; Nicotinic agonist . Cholinesterase inhibitor; Degenerative disease; Anticholinesterase agent; Nicotinic receptor; Alzheimer's disease; Nervous system diseases; Enzyme; Enzyme inhibitor; Antialzheimer agent; Carboxylic ester hydrolases; Parasympathomimetic; Cerebral disorder; A-85380; In vivo; Central nervous system disease; Hydrolases; Early; PET; Emission tomography
• ISSN: 0033-3158; 1432-2072